Company intelligence / Profile preview
Object Pharma
Newport Beach, California, United Statesobjectpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Object Pharma is developing OP01, a unique botulinum neurotoxin for the treatment of major depressive disorder and other mental health conditions. The company’s approach leverages evidence that botulinum neurotoxins can improve symptoms in depression. OP01 is designed to be clinically unique compared to existing products, with potential benefits including no drug-drug interactions and use as an adjunctive therapy. No published clinical results are available yet
- Therapeutic areas
- Psychiatry
- Modalities
- Botulinum neurotoxinBiologicProtein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Object Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Object Pharma.